Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Somerset's Eldepryl for Parkinson's will be copromoted by Cocensys.

Executive Summary

SOMERSET's ELDEPRYL WILL BE COPROMOTED BY CONCENSYS and its 70-person CNS field force in place of Sandoz after the end of the first quarter. Somerset Pharmaceuticals, the joint venture of Mylan Labs and Watson Pharmaceuticals, has signed on Cocensys to copromote selegiline for the treatment of Parkinson's disease in the U.S. Sandoz has been marketing the drug since Oct. 1, 1990. The companies agreed in 1995 to terminate that deal after March 31.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS027468

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel